广西医学Issue(8)：1096-1098,3.DOI:10.11675/j.issn.0253-4304.2014.08.24
厄洛替尼二线治疗化疗失败的晚期非小细胞肺癌的疗效观察
Effect of Erlotinib as Second-Line Therapy on Advanced Non-Small Cell Lung Cancer Following Failure of Chemotherapy
罗向晖 1曹燕飞 1陈耀华 1吴昱 1杨晔1
作者信息
- 1. 陕西省人民医院胸外科，西安市 710068
- 折叠
摘要
Abstract
Objective To observe the efficacy and safety of erlotinib as the second-line therapy for advanced non small cell lung cancer(NSCLC) following failure of first-line chemotherapy.Methods One hundred and six patients with advanced NSCLC following failure of first-line chemotherapy were randomly divided into experimental group (n=62) and control group(n=44).Two groups were both treated with docetaxel combined with cisplatin chemotherapy ,while erlotinib was added to the experimental group .The efficacy and adverse reactions were observed in two groups .Results In the experimental group,4 cases got CR,24 cases PR,28 cases SD and 6 cases PD,while in the control group ,CR were 0 cases,PR 13 cases,SD 14 cases and PD 17 cases.The efficacy in the experimental group was better than that in the control group(P<0.05).In the experimental group,the disease control rate (DCR) was 90.3%,the response rate ( RR) was 45.2%,while in the control group ,the DCR was 61.4%,the RR was 29.5%.The incidences of bone marrow suppression and gastrointestinal reaction in the experimental group were significantly lower than those in the control group(P<0.05).The 1-year survival rate in the experimental group was 64.5%(40/62),significantly higher than that (43.2%,19/44) in the control group(P<0.05).The median survival time,median time to progression,progression free survival and overall survival in the experimental group were significantly longer than those in the control group ( P<0 .05 ) .Conclusion Erlotinib as the second-line therapy for NSCLC following failure of chemotherapy has better curative effect and less adverse reactions .关键词
非小细胞肺癌/厄洛替尼/二线治疗/疗效Key words
Non-small cell lung cancer/Erlotinib/Second-line therapy/Efficacy分类
医药卫生引用本文复制引用
罗向晖,曹燕飞,陈耀华,吴昱,杨晔..厄洛替尼二线治疗化疗失败的晚期非小细胞肺癌的疗效观察[J].广西医学,2014,(8):1096-1098,3.
